Advertisement

Advanced glycation end products and diabetic retinopathy

  • Yashodhara Sharma
  • Sandeep SaxenaEmail author
  • Arvind Mishra
  • Anita Saxena
  • Shankar Madhav Natu
Article

Abstract

Studies have established hyperglycemia as the most important factor in the progress of vascular complications. Formation of advanced glycation end products (AGEs) correlates with glycemic control. The AGE hypothesis proposes that hyperglycemia contributes to the pathogenesis of diabetic complications including retinopathy. However, their role in diabetic retinopathy remains largely unknown. This review discusses the chemistry of AGEs formation and their patho-biochemistry particularly in relation to diabetic retinopathy. AGEs exert deleterious effects by acting directly to induce cross-linking of long-lived proteins to promote vascular stiffness, altering vascular structure and function and interacting with receptor for AGE, to induce intracellular signaling leading to enhanced oxidative stress and elaboration of key proinflammatory and prosclerotic cytokines. Novel anti-AGE strategies are being developed hoping that in next few years, some of these promising therapies will be successfully evaluated in clinical context aiming to reduce the major economical and medical burden caused by diabetic retinopathy.

Keywords

Advanced glycation end products (AGEs) Hyperglycemia Diabetes mellitus Microvascular disease Retinopathy 

Notes

Acknowledgments

The authors acknowledge the Junior Research Fellowship grant (F. no. 17-7/2011(SA-I)) from the University Grants Commission, India.

References

  1. 1.
    Singh R, Barden A, Mori T, et al. Advanced glycation end-products: a review. Diabetologia. 2001;44:129–46.PubMedCrossRefGoogle Scholar
  2. 2.
    Amos AF, McCarty DI, Zimmet P, et al. The rising global burden of diabetes and its complications: estimates and projections to 2010. Diabet Med. 1997;14(5):S1–S85.PubMedGoogle Scholar
  3. 3.
    Hanssen KF. Blood glucose control and microvascular and macrovascular complications. Diabetes. 1997;46(2):S101–3.PubMedGoogle Scholar
  4. 4.
    Šebeková K, Kupčová V, Schinzel R, et al. Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis-amelioration by liver transplantation. J Hepatol. 2002;36:66–71.PubMedCrossRefGoogle Scholar
  5. 5.
    DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRefGoogle Scholar
  6. 6.
    UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet. 1998;352:837–53.CrossRefGoogle Scholar
  7. 7.
    Brownlee M. Glycation and diabetic complications. Diabetes. 1994;43:836–41.PubMedGoogle Scholar
  8. 8.
    Bucala R, Cerami A. Advanced glycation: chemistry, biology and implications in diabetes in aging. Adv Pharmacol. 1992;23:1–34.PubMedCrossRefGoogle Scholar
  9. 9.
    Hammes HP, Weiss A, Hess S, Araki N, et al. Modification of vitronectin by advanced glycation alters functional properties in-vitro and the diabetic retina. Lab Invest. 1996;75:325–38.PubMedGoogle Scholar
  10. 10.
    John WG, Lamb EJ. The maillard or browning re-action in diabetes. Eye. 1993;7:230–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Schmidt AM, Hori O, Brett J, et al. Cellular receptors for advanced glycation end products: implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb. 1994;14:1521–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med. 1995;46:223–34.PubMedCrossRefGoogle Scholar
  13. 13.
    Schmidt AM, Yan SD, Wautier JL, et al. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489–97.PubMedCrossRefGoogle Scholar
  14. 14.
    Schmidt AM, Hasu M, Popov D, et al. Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc Natl Acad Sci U S A. 1994;91:8807–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Fu MX, Wells-Knecht KJ, Blackledge JA, et al. Glycation, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes. 1994;43:676–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Tanaka S, Avigad G, Brodsky B, et al. Glycation induces expansion of the molecular packing of collagen. J Mol Biol. 1988;203:495–505.PubMedCrossRefGoogle Scholar
  17. 17.
    Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999;48:1–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Suzuki D, Miyata T, Saotome N, et al. Immunohistochemical evidence for an increased oxidative stress and carbonyl modification of proteins in diabetic glomerular lesions. J Am Soc Nephrol. 1999;10:822–32.PubMedGoogle Scholar
  19. 19.
    Lo TW, Westwood ME, McLellan AC, et al. Binding and modification of proteins by methylglyoxal under physiological conditions: a kinetic and mechanistic study with N-α-acetylarginine, N-α-acetylcysteine, and N-α-acetyllysine, and bovine serum albumin. J Biol Chem. 1994;269:32299–305.PubMedGoogle Scholar
  20. 20.
    Frye EB, Degenhardt TP, Thorpe SR, et al. Role of the Maillard reaction in aging of tissue proteins. J Biol Chem. 1998;273:18714–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Ahmed MU, Thorpe SR, Baynes JW. Identification of N-ε-carboxymethyllysine as a degradation product of fructoselysine in glycated protein. J Biol Chem. 1986;261:4889–94.PubMedGoogle Scholar
  22. 22.
    Ledl F, Schleicher E. New aspects of the Maillard reaction in foods and in the human body. Angew Chem Int Ed Engl. 1990;6:565–94.CrossRefGoogle Scholar
  23. 23.
    Wells-Knecht KJ, Brinkmann E, Wells-Knecht MC, et al. New biomarkers of Maillard reaction damage to proteins. Nephrol Dial Transplant. 1996;11(5):41–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20.PubMedCrossRefGoogle Scholar
  25. 25.
    Thornalley JP. Advanced glycation and the development of diabetic complications: unifying the involvement of glucose, methylglyoxal and oxidative stress. Endocrinol Metab. 1996;3:149–66.Google Scholar
  26. 26.
    Cerami C, Founds H, Nicholl I, et al. Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci USA. 1997;94:13915–20.PubMedCrossRefGoogle Scholar
  27. 27.
    Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA. 1997;94:6474–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Nicholl ID, Stitt AW, Moore JE, et al. Increased levels of advanced glycation end products in the lenses and blood vessels of cigarette smokers. Mol Med. 1998;4:594–601.PubMedGoogle Scholar
  29. 29.
    Vlassara H, Cai W, Crandall J, et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA. 2002;99:15596–601.PubMedCrossRefGoogle Scholar
  30. 30.
    Henle T (2003) AGEs in foods: do they play a role in uremia? Kidney Int Suppl S145-S147.Google Scholar
  31. 31.
    Brownlee M, Vlassara H, Cerami A. Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein. Diabetes. 1985;34:938–41.PubMedCrossRefGoogle Scholar
  32. 32.
    Schmidt AM, Yan SD, Stern DM. The dark side of glucose. Nat Med. 1995;1:1002–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Garay-Sevilla ME, Regalado JC, Malacara JM, et al. Advanced glycosylation end products in skin, serum, saliva and urine and its association with complications of patients with type 2 diabetes mellitus. J Endocrinol Invest. 2005;28:223–30.PubMedGoogle Scholar
  34. 34.
    Rojas A, Morales MA. Advanced glycation and endothelial functions: a link towards vascular complications in diabetes. Life Sci. 2004;76:715–30.PubMedCrossRefGoogle Scholar
  35. 35.
    Brownlee M, Vlassara H, Cerami A. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med. 1988;318:1315–21.PubMedCrossRefGoogle Scholar
  36. 36.
    Eble AS, Thorpe SR, Baynes JW. Nonenzymatic glucosylation and glucose-dependent cross-linking of proteins. J Biol Chem. 1983;258:9506–12.Google Scholar
  37. 37.
    Fu MX, Knecht KJ, Thorpe SR, Baynes JW, et al. The role of oxygen in cross-linking and chemical modifications of collagen by glucose. Diabetes. 1992;41:42–8.PubMedGoogle Scholar
  38. 38.
    Sell DR, Lapolla A, Odetti P, et al. Pentosidine formation in skin correlates with severity of complication in individuals with long-standing IDDM. Diabetes. 1992;41:1286–92.PubMedCrossRefGoogle Scholar
  39. 39.
    Sell DR, Carlson EC, Monnier VM. Differential effects of type 2 (noninsulin-dependent) diabetes mellitus on pentosidine formation in skin and glomerular basement membrane. Diabetes. 1993;40:190–6.Google Scholar
  40. 40.
    Schleicher E, Nerlich A. The role of hyperglycaemia in the development of diabetic complications. Horm Metab Res. 1996;28:367–73.PubMedCrossRefGoogle Scholar
  41. 41.
    Vlassara H, Brownlee M, Cerami A. High-affinity receptor-mediated uptake and degradation of glucose modified proteins: a potential mechanism for the removal of senescent macromolecules. Procl Natl Acad Sci USA. 1985;82:5588–92.CrossRefGoogle Scholar
  42. 42.
    Higashi T, Sano H, Saishoji T, et al. The receptor for advanced glycation end products mediates the chemotaxis of rabbit smooth muscle cells. Diabetes. 1997;46:463–72.PubMedCrossRefGoogle Scholar
  43. 43.
    McCance DDG, Dunn JA, et al. Maillard reaction products and their relation to complications in insulin-dependent diabetes mellitus. J Clin Invest. 1993;91:2470–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Beisswenger PJ, Makita Z, Curphey TJ, et al. Formation of immunochemical advanced glycation endproducts precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes. 1995;44:824–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Chappey O, Dosquet C, Wautier M-P, et al. Advanced glycation end products, oxidant stress and vascular lesions. Eur J Clin Invest. 1997;27:97–108.PubMedCrossRefGoogle Scholar
  46. 46.
    Vlassara H, Baucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biological, and chemical implications for diabetes and aging. Lab Invest. 1994;70:138–51.PubMedGoogle Scholar
  47. 47.
    Stitt AW, Li YM, Gardiner TA, et al. Advanced glycated end-products(AGE) co-localise with AGE receptors in the retinal vasculature of diabetic and AGE infused rats. Am J Pathol. 1997;150:523–39.PubMedGoogle Scholar
  48. 48.
    Yamagishi S-C, Yonekura H, Yamamoto Y. Advanced glycation end product driven angiogenesis in vitro. J Biol Chem. 1997;272:8723–30.PubMedCrossRefGoogle Scholar
  49. 49.
    Monnier VM, Kohn RR, Cerami A. Accelerated age related browning of human in diabetes mellitus. Proc Natl Acad Sci USA. 1984;81:583–7.PubMedCrossRefGoogle Scholar
  50. 50.
    Doi T, Vlassara H, Kirstein M, et al. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc NatI Acad Sci USA. 1992;89:2873–7.CrossRefGoogle Scholar
  51. 51.
    Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest. 1991;87:432–8.PubMedCrossRefGoogle Scholar
  52. 52.
    Vlassara H, Fuh H, Makita Z, et al. Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications. Proc Natl Acad Sci USA. 1992;89:12043–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Vlassara H, Striker W, Teichberg S, et al. Advanced glycation endproducts induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA. 1994;91:11704–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Vlassara H, Fuh H, Donnelly T, et al. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med. 1995;1:447–56.PubMedGoogle Scholar
  55. 55.
    Stitt AW, Friedman S, Scher L, et al. Carotid artery advanced glycation end products and their receptors correlate with severity of lesion and with plasma AGE-ApoB levels in non-diabetic patients. FASEB J. 1996;10:A616.Google Scholar
  56. 56.
    Beisswenger PJ, Morre LL, Brinck-Johnsen T, et al. Increased collagen-like pentosidine levels and AGEs in early diabetic nephropathy. J Clin Invest. 1993;92:212–7.PubMedCrossRefGoogle Scholar
  57. 57.
    Araki N, Ueno N, Chakraharti B, et al. Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J Biol Chem. 1992;267:10211–4.PubMedGoogle Scholar
  58. 58.
    Schleicher ED, Wagner E, Nerlich AG. Increased accumulation of the glycoxidation product Nε-(carboxymethyl) lysine in human tissues in diabetes and aging. J Clin Invest. 1997;99:457–68.PubMedCrossRefGoogle Scholar
  59. 59.
    Cooper ME, Bonnet F, Oldfield M, et al. Mechanisms of diabetic vasculopathy: an overview. Am J Hypertens. 2001;14(1):475–86.PubMedCrossRefGoogle Scholar
  60. 60.
    Hammes HP, Alt A, Niwa T, et al. Differential accumulation of advanced glycation end products in the course of diabetic retinopathy. Diabetologia. 1999;42:728–36.PubMedCrossRefGoogle Scholar
  61. 61.
    Bucala R, Vlassara H. Advanced glycosylation end products in diabetic renal and vascular disease. Am J Kidney Dis. 1995;26:875–88.PubMedCrossRefGoogle Scholar
  62. 62.
    Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation end products in diabetic uraemia and treatment of renal failure. Lancet. 1994;343:1519–22.PubMedCrossRefGoogle Scholar
  63. 63.
    Ono Y, Aoki S, Ohnishi K. Increased serum levels of advanced glycation end-products and diabetic complications. Diabetes Res Clin Pract. 1998;41:131–7.PubMedCrossRefGoogle Scholar
  64. 64.
    Murata T, Nagai R, Ishibashi T. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas. Diabetologia. 1997;40:764–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Stitt AW. Advanced glycation: an important pathological event in diabetic and age related ocular disease. Br J Ophthalmol. 2001;85:746–53.PubMedCrossRefGoogle Scholar
  66. 66.
    Stitt AW, Moore JE, Sharkey JA, et al. Advanced glycation end products in vitreous: structural and functional implications for diabetic vitreopathy. Invest Ophthalmol Visual Sci. 1998;39:2517–23.Google Scholar
  67. 67.
    Fosmark DS, Bragadottir R, Stene-Johansen I, et al. Increased vitreous levels of hydroimidazolone in type 2 diabetes patients are associated with retinopathy: a case–control study. Acta Ophthalmol Scand. 2007;85:618–22.PubMedCrossRefGoogle Scholar
  68. 68.
    Gardiner TA, Anderson HR, Stitt AW, et al. Inhibition of advanced glycation end-products protects against retinal capillary basement membrane expansion during long-term diabetes. J Pathol. 2003;201:328–33.PubMedCrossRefGoogle Scholar
  69. 69.
    Schalkwijk CG, Ligtvoet N, Twaalfhoven H, et al. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes. 1999;48:2446–53.PubMedCrossRefGoogle Scholar
  70. 70.
    Hammes HP, Brownlee M, Edelstein D, et al. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia. 1994;37:32–5.PubMedCrossRefGoogle Scholar
  71. 71.
    Frank RN. On the pathogenesis of diabetic retinopathy. A 1990 update. Ophthalmology. 1991;98:586–93.PubMedGoogle Scholar
  72. 72.
    Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des. 2005;11:2279–99.PubMedCrossRefGoogle Scholar
  73. 73.
    Yamagishi S, Amano S, Inagaki Y, et al. Advanced glycation end productsinduced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes. Biochem Biophys Res Commun. 2002;290:973–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Yamagishi S, Inagaki Y, Amano S, et al. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product induced injury through its antioxidative properties. Biochem Biophys Res Commun. 2002;296:877–82.PubMedCrossRefGoogle Scholar
  75. 75.
    Yamagishi S, Amano S, Inagaki Y, et al. Beraprost sodium, a prostaglandin I2 analogue, protects against advanced gycation end products-induced injury in cultured retinal pericytes. Mol. Med. 2002;8:546–50.PubMedGoogle Scholar
  76. 76.
    Hammes HP, Lin J, Renner O, et al. Pericytes and the pathogenesis of diabetic retinopathy. Diabetes. 2002;51:3107–12.PubMedCrossRefGoogle Scholar
  77. 77.
    Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Murata T, Ishibashi T, Khalil A, et al. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res. 1995;27:48–52.PubMedCrossRefGoogle Scholar
  79. 79.
    Yamagishi S, Nakamura K, Matsui T, et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem. 2006;281:20213–20.PubMedCrossRefGoogle Scholar
  80. 80.
    Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 2002;16:1928–30.PubMedGoogle Scholar
  81. 81.
    Okamoto T, Yamagishi S, Inagaki Y, et al. Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro. Biochem Biophys Res Commun. 2002;297:419–24.PubMedCrossRefGoogle Scholar
  82. 82.
    Schroder S, Palinski W, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol. 1991;139:81–100.PubMedGoogle Scholar
  83. 83.
    Moore TC, Moore JE, Kaji Y, et al. The role of advanced glycation end products in retinal microvascular leukostasis. Investig Ophthalmol Vis Sci. 2003;44:4457–64.CrossRefGoogle Scholar
  84. 84.
    Lu M, Perez VL, Ma N, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Investig Ophthalmol Vis Sci. 1999;40:1808–12.Google Scholar
  85. 85.
    Yamagishi S, Matsui T, Nakamura K, et al. Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species. Ophthalmic Res. 2007;40:10–5.PubMedCrossRefGoogle Scholar
  86. 86.
    Inagaki Y, Yamagishi S, Okamoto T, et al. Pigment epitheliumderived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production inmicrovascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia. 2003;46:284–7.PubMedGoogle Scholar
  87. 87.
    Mitamura Y, Takeuchi S, Matsuda A, et al. Monocyte chemotactic protein-1 in the vitreous of patients with proliferative diabetic retinopathy. Ophthalmologica. 2001;215:415–8.PubMedCrossRefGoogle Scholar
  88. 88.
    Hammes HP, Martin S, Federlin K, et al. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA. 1991;88(11):555–58.Google Scholar
  89. 89.
    Chibber R, Molinatti PA, Wong JSK, et al. The effect of aminoguanidine and tolrestat on glucose toxicity in bovine retinal capillary pericytes. Diabetes. 1994;43:758–63.PubMedCrossRefGoogle Scholar
  90. 90.
    Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic study of diabetic retinopathy XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol. 1994;112:1217–28.PubMedCrossRefGoogle Scholar
  91. 91.
    Chibber R, Molinatti PA, Rosatto N, et al. Toxication of advanced glycation end products on cultured retinal capillary pericytes and endothelial cells: relevance to diabetic retinopathy. Diabetologia. 1997;40:156–64.PubMedCrossRefGoogle Scholar
  92. 92.
    Yamagishi S, Ueda S, Matsui T, et al. Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett. 2007;14:832–5.PubMedCrossRefGoogle Scholar
  93. 93.
    Schmidt AM, Hori O, Chen JX, et al. Advanced glycation end products interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: a potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 1995;96:1395–403.PubMedCrossRefGoogle Scholar
  94. 94.
    Howard EW, Benton R, Ahern-Moore J, et al. Cellular contraction of collagen lattices is inhibited by nonenzymatic glycation. Exp Cell Res. 1996;228:132–7.PubMedCrossRefGoogle Scholar
  95. 95.
    Haitoglou CS, Tsilibary EC, Brownlee M, et al. Altered cellular interactions between endothelial cells and nonenzymatically glucosylated laminin/type IV collagen. J Biol Chem. 1992;267:12404–7.PubMedGoogle Scholar
  96. 96.
    Koga K, Yamagishi S, Okamoto T, et al. Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction. Int J Clin Pharmacol Res. 2002;22:13–7.PubMedGoogle Scholar
  97. 97.
    Turk Z, Ljubic S, Turk N, et al. Detection of autoantibodies against glycation end products and AGE immune complexes in serum of patients with diabetes mellitus. Clin Chim Acta. 2001;303:105–15.PubMedCrossRefGoogle Scholar
  98. 98.
    Sugiyama S, Miyata T, Ueda Y, et al. Plasma levels of pentosidine in diabetic patients: an advanced glycation end product. J Am Soc Nephrol. 1998;9:1681–8.PubMedGoogle Scholar
  99. 99.
    Wagner Z, Wittmann I, Mazak I, et al. N(epsilon)-(carboxymethyl) lysine levels in patients with type 2 diabetes: role of renal function. Am J Kidney Dis. 2001;38:785–91.PubMedCrossRefGoogle Scholar
  100. 100.
    Dorrian CA, Cathcart S, Clausen J, et al. Factors in human serum interfere with the measurement of advanced glycation end products. Cell Mol Biol. 1998;44:1069–79.PubMedGoogle Scholar
  101. 101.
    Genuth S, Sun W, Cleary P, et al. DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 2005;54:3103–11.PubMedCrossRefGoogle Scholar
  102. 102.
    Hartog JW, de Vries AP, Lutgers HL, et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann NY Acad Sci. 2005;1043:299–307.PubMedCrossRefGoogle Scholar
  103. 103.
    Bierhaus A, Hofmann MA, Ziegler R, et al. AGE and their interaction with AGE-receptors in vascular disease and diabetes. I. The AGE cononcept. Cardiovasc Res. 1998;37:586–600.PubMedCrossRefGoogle Scholar
  104. 104.
    Khalifah RG, Baynes JW, Hudson BG. Amadorins: novel post-amadori inhibitors of advanced glycation end-products. Biochem and Biophysical Res Commun. 1999;257:251–8.CrossRefGoogle Scholar
  105. 105.
    Koschinsky T, He CJ, Mitsuhashi T, et al. Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A. 1997;94:6474–9.PubMedCrossRefGoogle Scholar
  106. 106.
    Goldberg T, Cai W, Peppa M, et al. Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc. 2004;104:1287–91.PubMedCrossRefGoogle Scholar
  107. 107.
    Uribarri J, Peppa M, Cai W, et al. Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol. 2003;14:728–31.PubMedCrossRefGoogle Scholar
  108. 108.
    Yamagishi S, Nakamura K, Matsui T, et al. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders. Med Hypotheses. 2007;69:666–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Yashodhara Sharma
    • 1
  • Sandeep Saxena
    • 1
    Email author
  • Arvind Mishra
    • 2
  • Anita Saxena
    • 3
  • Shankar Madhav Natu
    • 4
  1. 1.Department of OphthalmologyKing George Medical UniversityLucknowIndia
  2. 2.Department of MedicineKing George Medical UniversityLucknowIndia
  3. 3.Department of NephrologySanjay Gandhi Post Graduate Institute of Medical SciencesLucknowIndia
  4. 4.Department of PathologyKing George Medical UniversityLucknowIndia

Personalised recommendations